Related Experiment Video
Updated: May 2, 2026
12:50
Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
Published on: September 15, 2017
6.0K
Beta-endorphin 1-31 biotransformation and cAMP modulation in inflammation
Naghmeh Hajarol Asvadi1, Michael Morgan1, Herath M Herath1
1School of Pharmacy, The University of Queensland, Brisbane, Queensland, Australia.
Plos One
|March 13, 2014
Summary
Inflammation degrades beta-endorphin (BE 1-31), but its fragments retain opioid receptor activity. These fragments may contribute to BE 1-31
Area of Science:
- Immunology
- Neuroscience
- Biochemistry
Background:
- Immune cells release beta-endorphin (BE 1-31) in inflamed tissues.
- Inflammatory environments (acidic, high temperature) accelerate BE 1-31 degradation.
- BE 1-31 fragments may have distinct biological roles in inflammation.
Purpose of the Study:
- To investigate the biotransformation pathways of BE 1-31 in inflamed tissue.
- To assess the opioid receptor activity of BE 1-31 and its N-terminal fragments.
- To understand the contribution of BE 1-31 fragments to inflammatory conditions.
Main Methods:
- Incubation of BE 1-31 and fragments in inflamed tissue homogenates (pH 5.5).
- Assessment of opioid receptor potency (MOR, DOR, KOR) via cAMP accumulation.
- Quantification of peptide presence in inflamed tissue.
Main Results:
- Most N-terminal fragments showed similar efficacy to BE 1-31 at MOR.
- BE 1-9 fragment exhibited partial agonist activity at MOR and highest potency at DOR.
- Limited activity was observed at KOR for BE 1-31 and its fragments.
Conclusions:
- Major N-terminal fragments of BE 1-31 are more prevalent in inflamed tissue.
- These fragments retain significant opioid receptor activity, particularly at DOR.
- BE 1-31 fragments may contribute to the overall efficacy of beta-endorphin in inflammatory diseases.
Related Concept Videos
01:25Analgesia and Pain Management
3.3K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
3.3K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
02:26NF-κB-dependent Signaling Pathway
7.6K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.6K
01:25Acute Inflammation II: Local and Systemic Effects
56
Acute inflammation produces a coordinated set of local and systemic changes that limit injury, eliminate pathogens, and initiate repair. These responses arise within minutes of infection, trauma, or chemical insult and are driven by vascular alterations and leukocyte-derived mediators. When the stimulus resolves, the reaction typically abates within days.Local EffectsAt the site of injury, arteriolar vasodilation increases blood flow, resulting in redness and warmth. Simultaneously, increased...
56
01:22Opioid Receptors: Overview
7.2K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
7.2K
01:16Drug Biotransformation: Overview
3.7K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
3.7K